SCHEMBL17153115

SCHEMBL17153115

CN(CCN(C)c1ccc(-c2ccnc(Nc3cccc(CO)c3)n2)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK19 Q9BWU1 2/20 0.44
CDC7 O00311 1/20 0.44
EPHB4 P54760 1/20 0.42
ABL1 P00519 5/20 0.41
BCR P11274 4/20 0.41
SRC P12931 2/20 0.41
SYK P43405 2/20 0.39
PIK3CG P48736 3/20 0.39
MAPK8 P45983 3/20 0.39
JAK2 O60674 2/20 0.39
PRKCA P17252 2/20 0.39
GSK3B P49841 2/20 0.39
CAMKK2 Q96RR4 2/20 0.39
FLT3 P36888 1/20 0.39
IKBKB O14920 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
CAMK2D Q13557 1/20 0.39
JAK3 P52333 1/20 0.39
ALK Q9UM73 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17153054 0.95 CDK19 (0.43) CDK19CDC7EPHB4ABL1BCR
SCHEMBL17153055 0.87 CDC7 (0.46) CDK19CDC7EPHB4ABL1BCR
SCHEMBL17153127 0.86 CDC7 (0.41) CDK19CDC7EPHB4ABL1BCR
SCHEMBL17152801 0.86 CDC7 (0.43) CDK19CDC7EPHB4ABL1BCR
SCHEMBL17152975 0.86 CCNT1 (0.43) CDK19CDC7SYKPIK3CGMAPK8
SCHEMBL17153046 0.86 CDC7 (0.36) CDK19CDC7ABL1BCRSRC
SCHEMBL12921629 0.85 ABL1 (0.40) CDK19CDC7ABL1BCRJAK2
SCHEMBL17153113 0.85 CDK1 (0.45) CDK19CDC7EPHB4ABL1BCR
SCHEMBL17153086 0.85 JAK2 (0.40) CDK19CDC7ABL1BCRSRC
SCHEMBL17152981 0.85 IKBKB (0.40) CDK19CDC7ABL1BCRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
EP-3126364-B1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2018-02-07 EP disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 US disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 CDK19 979/4885CDC7 1539/4885EPHB4 900/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 CDK19 979/4885CDC7 1539/4885EPHB4 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.